ASC

PPG opens $17 million aerospace application support center in France

Retrieved on: 
Tuesday, December 12, 2023

PPG (NYSE:PPG) today announced the opening of a $17 million aerospace application support center (ASC) in Toulouse, France.

Key Points: 
  • PPG (NYSE:PPG) today announced the opening of a $17 million aerospace application support center (ASC) in Toulouse, France.
  • View the full release here: https://www.businesswire.com/news/home/20231212364862/en/
    PPG has opened a $17 million aerospace application support center in France that will ensure fast product delivery to regional customers.
  • (Photo: Business Wire)
    “PPG is a critical supplier to the aerospace industry, with a suite of technologically advanced products,” said Francois Buehlmann, PPG general manager EMEA, Aerospace.
  • “We are thrilled to provide convenient access to our aerospace products and services while further committing to our investment in France,” said Dan Korte, PPG senior vice president, Aerospace.

Shanghai University to Host Finals of the 2024 ASC Student Supercomputer Challenge

Retrieved on: 
Friday, December 8, 2023

The ASC Student Supercomputer Challenge 2024 (ASC24) gladly announces that the highly anticipated ASC24 finals will be hosted at Shanghai University.

Key Points: 
  • The ASC Student Supercomputer Challenge 2024 (ASC24) gladly announces that the highly anticipated ASC24 finals will be hosted at Shanghai University.
  • The ASC Student Supercomputer Challenge, renowned as the foremost global competition in student supercomputing, is meticulously organized and sponsored by the Asia Supercomputer Community.
  • Since its establishment in 2012, the ASC Student Supercomputer Challenge has attracted the participation of nearly 10,000 undergraduate students from diverse locations around the globe.
  • Shanghai University (SHU), founded in 1922, has evolved into a university with profound academic traditions and outstanding research facilities.

Exactech Announces FDA 510(k) Clearance of the World’s First Surgical Navigation for Total Ankle Replacement

Retrieved on: 
Tuesday, December 5, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231205596021/en/
    Exactech Announces FDA 510(k) Clearance of the World’s First Surgical Navigation for Total Ankle Replacement (Photo: Business Wire)
    GPS Ankle is a first-of-its-kind technology, which connects the preoperative plan with real-time intraoperative instrument guidance and confirms that resections meet the surgical plan.
  • “I am already a fan of Exactech’s patient-specific instrumentation solution and am thrilled how GPS Ankle provides intraoperative flexibility at my fingertips.
  • GPS Ankle is compatible with Exactech’s flagship Vantage® Total Ankle System , and will be available to hospitals and ASC centers without capital cost.
  • GPS, Equinoxe Planning App and Predict+ are developed by Blue Ortho, an Exactech subsidiary, and distributed by Exactech, Inc.

Applied StemCell, Inc. Strengthens Executive Leadership with Two Key Appointments

Retrieved on: 
Monday, December 4, 2023

The recent acquisition of the company by QHP Capital in October has set the stage for an ambitious expansion focused on supporting cell manufacturing from development through commercialization.

Key Points: 
  • The recent acquisition of the company by QHP Capital in October has set the stage for an ambitious expansion focused on supporting cell manufacturing from development through commercialization.
  • George Hong joins Applied StemCell, Inc. as Chief Commercial Officer (CCO), bringing more than 20 years of experience in academic and industry roles within life sciences, serving as a sales, marketing, and commercial executive with increasing responsibilities.
  • Prior to joining Applied StemCell, Tim held key positions, including VP of Commercial Manufacturing at Adrian Biotech, VP of Manufacturing Science and Technology (MSAT) at RoslinCT, and over 8 years in commercial manufacturing and quality positions at Dendreon.
  • "We are thrilled to have George and Tim as valuable additions to the ASC leadership team," expressed Dr. Ruby Chen-Tsai, CEO of Applied StemCell.

Trilliant Health’s Market Explorer Application Provides a Comprehensive View of Local Healthcare Markets

Retrieved on: 
Wednesday, November 29, 2023

Trilliant Health, the healthcare industry’s leading analytics firm, today released its Market Explorer , a point-and-click application that provides a more accurate understanding of network performance at the local market level.

Key Points: 
  • Trilliant Health, the healthcare industry’s leading analytics firm, today released its Market Explorer , a point-and-click application that provides a more accurate understanding of network performance at the local market level.
  • View the full release here: https://www.businesswire.com/news/home/20231129199263/en/
    Market Explorer is a user-friendly application that provides a more accurate understanding of market share and network performance.
  • Everyone in the healthcare industry reports their market share inaccurately, because they underestimate the number of competitors in their market.
  • Market Explorer enables every healthcare provider to understand the most concerning trends and competitive opportunities in their market.”

ASC Therapeutics Doses First Patient with ASC618 Second-Generation Gene Therapy for Hemophilia A

Retrieved on: 
Wednesday, November 29, 2023

ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic and other rare disorders, today announced that the first patient has been dosed in the company’s Phase I/IIa clinical trial of the lead candidate, ASC618, at the Arkansas Children’s Hospital.

Key Points: 
  • ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic and other rare disorders, today announced that the first patient has been dosed in the company’s Phase I/IIa clinical trial of the lead candidate, ASC618, at the Arkansas Children’s Hospital.
  • ASC618 is an investigational second-generation gene therapy for patients with severe and moderately severe hemophilia A.
  • Oscar Segurado, MD, PhD, ASC Therapeutics’ Chief Medical Officer said, “This is a special day for ASC Therapeutics and for patients with hemophilia A hoping to access a more durable and affordable second-generation gene therapy.
  • We are now assessing in a clinical setting the relevance of a novel one-and-done gene therapy that may replace lifelong, burdensome, and expensive treatments to manage hemophilia A.”

Exactech AI Platform Surpasses 100,000 Joint Replacement Surgeries Worldwide

Retrieved on: 
Monday, November 20, 2023

Exactech , a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today its Active Intelligence® (AI) platform surpassed more than 100,000 total joint replacement surgeries across the globe.

Key Points: 
  • Exactech , a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today its Active Intelligence® (AI) platform surpassed more than 100,000 total joint replacement surgeries across the globe.
  • View the full release here: https://www.businesswire.com/news/home/20231120575358/en/
    Exactech Active Intelligence® (AI) empowers surgeons with data-rich, low-cost solutions that help improve patient outcomes.
  • “As a leader in orthopaedic innovations, Exactech is focused on pushing technological boundaries to deliver a best-in-class platform of enabling technologies and smart solutions.
  • ExactechGPS, Equinoxe Planning App and Predict+ are developed by Blue Ortho, an Exactech subsidiary, and distributed by Exactech, Inc.

Regent Surgical Health and Oregon Surgical Institute Expand Partnership

Retrieved on: 
Thursday, November 16, 2023

Regent Surgical Health (“Regent” or the “Company”), a national platform of ambulatory surgery centers specializing in health system joint venture partnerships, announced today that it has expanded its successful joint venture partnership with Oregon Surgical Institute (OSI).

Key Points: 
  • Regent Surgical Health (“Regent” or the “Company”), a national platform of ambulatory surgery centers specializing in health system joint venture partnerships, announced today that it has expanded its successful joint venture partnership with Oregon Surgical Institute (OSI).
  • As a result of the agreement, Regent has gained majority ownership of OSI, an internationally recognized outpatient surgery center specializing in complex cases.
  • “Regent’s increased investment will further enable the world-class clinical team at Oregon Surgical Institute to focus on the delivery of industry-leading care, while also excelling the orthopedic and total joint space in general,” said Jeff Andrews, Regent’s Chief Operating Officer.
  • Regent develops, owns, and manages multispecialty ASC facilities in markets across the United States, successfully growing its footprint through a focused strategy to develop multisite health system partnerships.

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023.

Key Points: 
  • AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023.
  • On October 31, 2023, AgeX made a final draw of loan funds available under a line of credit from Juvenescence Limited.
  • Cash, cash equivalents, and restricted cash totaled $0.4 million as of September 30, 2023.
  • These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.

Firsthand Technology Value Fund Announces Third Quarter Financial Results, NAV of $0.10 Per Share

Retrieved on: 
Tuesday, November 14, 2023

During the quarter, the Fund suffered material setbacks in IntraOp Medical Corp. and Wrightspeed, Inc., two of its largest holdings at the start of the quarter.

Key Points: 
  • During the quarter, the Fund suffered material setbacks in IntraOp Medical Corp. and Wrightspeed, Inc., two of its largest holdings at the start of the quarter.
  • Effective September 30, 2023, the Fund has entered into a fee waiver agreement with its investment adviser, Firsthand Capital Management, Inc. (“FCM”).
  • For the quarter ended September 30, 2023, the Fund reported a total investment loss of approximately $0.2 million.
  • The Fund reported net realized and unrealized losses on investments of approximately $12.3 million for the quarter.